CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
Oxycodone IN +1 moredrug
Likely dose
Oxycodone IN 0.1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07223450
NCT07223450Phase 1Completed

Physiologically Based Pharmacokinetic Modelling of Oral and Intranasal Formulations of Oxycodone in Healthy Volunteers

Parc de Salut Mar·interventional·Posted Oct 31, 2025·Updated May 6, 2026

In Brief

A Phase 1 clinical trial evaluating Oxycodone IN and oxycodone for Physiologically Based Pharmacokinetic and Healthy Volunteers. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This is a single-dose, 2-period, 2-sequence, fasting, open label, crossover randomized design, comparing the pharmacokinetics (PK) and pharmacodynamics (PD) of intranasal and oral oxycodone solutions. The aim will be to characterize the PK and PD of two formulations of oxycodone (intranasal and oral) in healthy subjects, which will be used to verify/validate nasal-CNS-PBPK (Physiologically Based Pharmacokinetic) model predictions following intranasal dosing. A total of 8 healthy male/female subjects will be randomly assigned to one of two sequences in the crossover study. All subjects will receive the same dosage of oxycodone intranasal or oral and the sequence will be determined following randomization.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSpain

Timeline

Phase 1CompletedFinished
2026
First PostedOct 31, 2025
Enrollment StartJun 12, 2025
Primary CompletionOct 7, 2025
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8 months ago

Interventions

Oxycodone INdrug

0.1 mg/kg intravenously oxycodone solution administered intranasally

oxycodonedrug

oral solution 0.1 mg/kg